Moderna's mRNA flu shot earns FDA approval after rollercoaster review
Moderna's new flu vaccine, mFLUSIVA, is approved for all adults ages 50 and up.
Moderna's new flu vaccine, mFLUSIVA, is approved for all adults ages 50 and up.
The short version
- Moderna’s new flu vaccine, mFLUSIVA, is approved for all adults ages 50 and up.
- Despite significant drama from Trump officials this year, the Food and Drug Administration has for the first time approved a flu vaccine that uses mRNA technology.
- On Thursday, vaccine maker Moderna announced that its flu shot, mRNA-1010, aka mFLUSIVA, had earned approval for use in all adults ages 50 and up.
What happened
The approval announcement follows a unanimous vote by FDA advisors in June to approve the vaccine . That vote was based on its superior efficacy to existing seasonal flu shots and a good safety record demonstrated in trials that included nearly 44,000 people.
Why it matters
After that vote, the FDA set a goal of August 5 for a decision on the vaccine’s fate.
Summary by Nerd News Network. Read the full article at Ars Technica via the links above and below.